The use of β3-AR agonists as potential therapeutics for obesity and type-2 diabetes has been pursued intensively in the recent past, but lack of efficacy or side effects (mainly due to adrenergic stimulation of the cardiovascular system) have prevented translation to clinical application46. This evidence concerns the gene ADRB3 and type 2 diabetes mellitus.